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Abstract
Introduction Breast cancer metastasis is a complex, multi-step
biological process. Genetic mutations along with epigenetic
alterations in the form of DNA methylation patterns and histone
modifications contribute to metastasis-related gene expression
changes and genomic instability. So far, these epigenetic
contributions to breast cancer metastasis have not been well
characterized, and there is only a limited understanding of the
functional mechanisms affected by such epigenetic alterations.
Furthermore, no genome-wide assessments have been
undertaken to identify altered DNA methylation patterns in the
context of metastasis and their effects on specific functional
pathways or gene networks.
Methods We have used a human gene promoter tiling
microarray platform to analyze a cell line model of metastasis to
lymph nodes composed of a poorly metastatic MDA-MB-
468GFP human breast adenocarcinoma cell line and its highly
metastatic variant (468LN). Gene networks and pathways
associated with metastasis were identified, and target genes
associated with epithelial–mesenchymal transition were
validated with respect to DNA methylation effects on gene
expression.
Results We integrated data from the tiling microarrays with
targets identified by Ingenuity Pathways Analysis software and
observed epigenetic variations in genes implicated in
epithelial–mesenchymal transition and with tumor cell migration.
We identified widespread genomic hypermethylation and
hypomethylation events in these cells and we confirmed
functional associations between methylation status and
expression of the CDH1, CST6, EGFR, SNAI2 and ZEB2 genes
by quantitative real-time PCR. Our data also suggest that the
complex genomic reorganization present in cancer cells may be
superimposed over promoter-specific methylation events that
are responsible for gene-specific expression changes.
Conclusion This is the first whole-genome approach to identify
genome-wide and gene-specific epigenetic alterations, and the
functional consequences of these changes, in the context of
breast cancer metastasis to lymph nodes. This approach allows
the development of epigenetic signatures of metastasis to be
used concurrently with genomic signatures to improve mapping
of the evolving molecular landscape of metastasis and to permit
translational approaches to target epigenetically regulated
molecular pathways related to metastatic progression.
468GFP = MDA-MB-468GFP breast adenocarcinoma cells; 468LN = MDA-MB-468LN breast adenocarcinoma cells; EMT = epithelial–mesenchy-
mal transition; IPA = Ingenuity Pathways Analysis; PCR = polymerase chain reaction; qRT-PCR = quantitative real-time RT-PCR; RT = reverse tran-
scriptase; UCSC = University of California at Santa Cruz.Breast Cancer Research    Vol 10 No 4    Rodenhiser et al.
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Introduction
Metastasis is a complex, multi-step biological process charac-
terized by distinct, interrelated steps that vary in their timing
and efficiency [1,2]. These steps include the invasion of pri-
mary tumor cells into the surrounding tissue, intravasation into
and through the local blood or lymphatic circulation, extravasa-
tion from the circulation and arrest of the tumor cell at a sec-
ondary site, and finally the colonization and growth of
metastatic cells at that distant location [2-4]. Complex genetic
and epigenetic alterations govern the efficiency of each of
these steps. However, the molecular characteristics of metas-
tasis in general, and breast cancer metastasis in particular, are
primarily understood in the context of genetic changes identi-
fied with the use of gene-specific, tissue-specific and whole-
genome approaches. For example, individual metastasis sup-
pressor genes have been identified that, when lost or mutated,
are permissive to the metastatic or invasive phenotype [5,6]. In
addition, various microarray studies have generated genetic
signatures of metastasis related to risk [7,8], clinical outcome
[9] and distant recurrence [10], and have identified candidates
for targeted therapy [11-13].
In contrast, epigenetic alterations in metastasis are less well
characterized than these genetic changes [9,14]. Such epige-
netic alterations primarily involve DNA hypermethylation
events within the promoter regions of individual candidate
genes. This reversible addition of methyl groups at cytosines
within CpG dinucleotides can promote the recruitment of pro-
tein complexes that repress transcription and also prevent the
binding of transcription factors to their binding motifs [15,16].
Additionally, the hypomethylation of repetitive elements can
occur and leads to genomic instability [17,18], and alterations
in histone protein modifications can have profound conse-
quences that contribute to cancer and define an epigenetic
signature of tumorigenesis [16,19,20].
Studies addressing epigenetic contributions to breast cancer
metastasis have primarily focused on mapping increased DNA
methylation within the promoter regions of individual candidate
genes or small sets of cancer-related genes [21]. For example,
hypermethylation of the E-cadherin (CDH1) promoter, and the
resultant decrease in its expression, are associated with infil-
trating breast cancers [22]. A limited hypermethylation profile
associated with sentinel lymph node metastasis has been
described that also involves significant hypermethylation in
CDH1, with measureable methylation also evident in
RASSF1A, RAR-β 2, APC, TWIST and GSTP1 [23]. In some
cases, promoter hypermethylation has been correlated with
specific tumor characteristics, such as GSTP1 methylation
with increased tumor size, the occurrence of CDH1 methyla-
tion in estrogen receptor (ESR1)-negative tumors and the fre-
quent appearance of RAR-β 2 hypermethylation in HER2-
positive tumors [23]. Similar multi-gene correlations have
linked metastases of breast cancer cells to sentinel lymph
nodes with epigenetic alterations in CDH1 and RAR-β 2 [24]
and hypermethylation of ESR1, BRCA1 and CDH1 in breast
LN metastases [25]. Promoter methylation has also been
observed in a wide variety of essential molecular pathways in
the context of metastatic breast cancer, including genes
involved in apoptosis [26], DNA repair [27,28], the regulation
and composition of the extracellular matrix [29,30], transcrip-
tion [31,32] and the cell cycle [33,34]. In addition, epigenetic
silencing of the lysosomal cysteine protease inhibitor cystatin
6 (CST6) is more frequently observed in metastatic lesions
than in primary cancers [35] and the epigenetic silencing of
the chemokine CXCL12 (rather than its receptor CXCR4)
contributes to the metastatic potential of mammary carcinoma
cells [36]. In contrast with the repressive effects of promoter
hypermethylation, hypomethylation events can lead to gene
overexpression that can significantly stimulate breast cancer
progression and metastasis [37] as well as being an effective
molecular indicator of distant metastases [38].
Despite these various reports, no systematic assessments
have been performed to identify genome-wide DNA methyla-
tion signatures related to models of breast cancer metastasis.
Here we describe the first use of promoter tiling microarrays to
identify whole-genome epigenetic changes associated with
breast cancer metastasis to lymph nodes. We used a highly
metastatic variant (MDA-MB-468GFP-LN; 468LN) of the
poorly metastatic MDA-MB-468GFP human breast adenocar-
cinoma cell line [39]. In breast cancer, the lymphatic system
serves as a direct route for the spread of primary tumor cells
to the lymph nodes and is also a potential route for dissemina-
tion throughout the body to distant organs. This variant 468LN
cell line displays profound morphological changes and
increased growth rate relative to its parental line, and when
injected orthotopically into nude mice, these cells produce
abundant spontaneous lymph node metastases [39]. We
identified widespread hypomethylation and hypermethylation
events in these cells by using promoter tiling microarrays and
we identified the altered DNA methylation status of several
genes implicated in epithelial–mesenchymal transition (EMT)
[40]. Furthermore, we confirmed functional associations
between this altered methylation status and changes in gene
expression with quantitative real-time RT-PCR (qRT-PCR).
Here we show for the first time that genome-wide epigenetic
alterations may contribute to metastasis through the lymph
nodes and that these epigenetic changes are functionally
associated with metastatic mechanisms such as EMT.
Materials and methods
Cell lines
MDA-MB-468GFP (468GFP) and 468LN cell lines were iso-
lated and characterised as described previously [39] and
grown for four passages from frozen stocks in α-minimum
essential medium (Invitrogen, Burlington, ON, Canada) sup-
plemented with 10% fetal calf serum (Wisent Inc., St Bruno,
Quebec, Canada). At the fifth passage, each cell line was split
into three parallel flasks designated biological replicate 1, 2Available online http://breast-cancer-research.com/content/10/4/R62
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and 3, and grown to approximately 70% confluence. All exper-
imental research reported in this article was performed within
the Safety and Ethical guidelines of the University of Western
Ontario.
Digestion of purified genomic DNA with MseI and 
ligation to annealed adaptor primers
An adaptor-mediated, PCR-based approach was used to pro-
duce labeled targets for microarrays (Figure 1a). For each cell
line, 2 μg of genomic DNA was isolated with the GenElute
Genomic DNA Miniprep kit (Sigma-Aldrich, St Louis, MO,
USA) in accordance with the manufacturer's instructions and
was digested with 10 U of MseI (New England Biolabs, Pick-
ering, ON, Canada) in 1 × NEB2 buffer in a final volume of 50
μl for 3 hours at 37°C. MseI-digested genomic DNA was then
purified with the Qiaquick PCR Purification kit (Qiagen, Mis-
sissauga, ON, Canada) and eluted in 50 μl. H-12 and H-24
primers were annealed as follows: 4 nmol of H-24 (5'-AGG
CAA CTG TGC TAT CCG AGG GAT-3'; Sigma-Genosys,
Oakville, ON, Canada) and 4 nmol of H-12 (5'-TAA TCC CTC
GGA-3'; Sigma-Genosys) were combined in a final volume of
16 μl, heated to 80°C for 5 minutes and then allowed to cool
slowly to 20°C. The annealed primers were then combined
with the MseI digested, purified genomic DNA, 5 U of T4 DNA
ligase (Invitrogen) and 1 × ligase buffer in a final volume of 80
μl, and the samples were ligated overnight at 16°C. The adap-
tor-ligated genomic DNA was later purified with the Qiaquick
PCR cleanup kit, eluted in 30 μl, digested with HhaI in a 50 μl
volume for 3 hours at 37°C and then purified. Regions of dif-
ferential methylation in DNA from both cell lines were deter-
mined by comparing signal intensities on microarrays.
PCR amplification of adaptor-ligated, HhaI-digested 
genomic DNA
To generate amplicons for labeling hybridization to microar-
rays, the purified adaptor-ligated, HhaI-digested DNA was
amplified in 50 μl with 1 U of Taq polymerase (Invitrogen), 1 ×
reaction buffer, dATP, dCTP and dGTP (each at 200 μM), 160
μM dTTP, 40 μM dUTP and 1.0 μM H-24 primer. The reaction
profile consisted of the following: 72°C for 5 minutes, followed
by 25 cycles of 94°C for 1 minute, 55°C for 1.5 minutes and
72°C for 2 minutes, with a final extension step of 72°C for 10
minutes. PCR reactions were then purified as above and
eluted in 50 μl. For each biological replicate, 7.5 μg of ampli-
fied DNA was fragmented, labeled, and hybridized to Human
Promoter 1.0R GeneChips (Affymetrix, Santa Clara, CA,
USA), and the arrays were washed and scanned in accord-
ance with the manufacturer's standard protocol. Array Image
analysis and spot quantification were performed with Affyme-
trix GeneChip Operating Software (GCOS) software from
Affymetrix. All microarray analyses were performed at the Lon-
don Regional Genomics Centre and all sequencing was per-
formed at the Robarts Sequencing Facility at the University of
Western Ontario.
Microarray data analysis
The .CEL files (raw methylation measurements generated by
GCOS) were then imported into the Partek Genomic Suite
Software [41-43]. The imported data were normalized with the
Robust Multichip Averaging algorithm [44] and converted to
log2 values. To detect hypermethylated regions, the mean sig-
nal from each probe for the 468GFP cells was subtracted
from that of the 468LN cells across all 4.2 million probes. All
probes with a positive signal after this subtraction represented
regions of increased signal in 468LN cells. (A reverse subtrac-
tion was performed to detect regions of significant hypometh-
ylation.) Statistical parameters were set at P < 0.05 (single-
sided t test), with a window of 250 nucleotides, to detect sig-
nificant regions present in at least two of three biological rep-
licates. These regions were annotated to their corresponding
genes with the use of the Probeset ID annotation file from the
Affymetrix U133_Plus_2 Expression Array. The 'Chromosome
View' tool of the Partek Genomic Suite software visualized
hypermethylation/hypomethylation across an entire chromo-
some; to visualize methylation events at specific promoters,
the 'Region View' tool of this software was used to create cus-
tom tracks (.wig files) for visualization in the University of Cali-
fornia at Santa Cruz (UCSC) Blat genome browser [45].
The data discussed in this publication have been deposited in
the National Center for Biotechnology Information's Gene
Expression Omnibus (GEO) and are accessible through GEO
Series accession number GSE12122.
Bisulfite genomic sequencing
To confirm DNA methylation status [46], genomic DNA (2 μg)
was treated with bisulfite using the Epitect DNA bisulfite treat-
ment kit (Qiagen). Primers specific to the converted DNA were
designed with the MethPrimer software [47], using the default
parameters for 200 and 500 base-pair amplicons. PCR was
performed with 60 ng of DNA in 1 × buffer, 200 μM dNTPs,
2.0 to 2.5 mM MgCl2, 400 nM forward and reverse primers
(Sigma-Genosys), and 1 U of Taq polymerase. The cycling
conditions used were asa follows: 1 cycle of 94°C for 5 min-
utes, followed by 5 cycles of 94°C for 1 minute, 55°C for 2
minutes and 72°C for 2.5 minutes, followed by 35 cycles of
94°C for 1 minute, 55°C for 1 minute and 72°C for 1.5 min-
utes. PCR products were purified from agarose gels with the
Qiaquick PCR Purification kit, and 25 ng of purified product
was ligated overnight at 14°C into the T-vector PCR2.1 (Invit-
rogen) in accordance with the manufacturer's instructions.
Plasmids were transformed into TOP10 competent bacteria,
and transformed bacteria were spread onto Luria–Bertani agar
plates containing 100 μg/ml ampicillin and 50 μl of 10 mg/ml
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and
incubated overnight at 37°C. Potential clones were directly
screened by PCR with the gene-specific primers, and clones
showing the expected band size were inoculated into 2 ml of
LB containing 100 μg/ml ampicillin and grown overnight at
37°C. Plasmid DNA was isolated with the Genelute PlasmidBreast Cancer Research    Vol 10 No 4    Rodenhiser et al.
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Miniprep kit (Sigma, Oakville, ON, Canada) and sequenced
with the T7 promoter primer, and cloned sequences were ana-
lyzed by using the ClustalW alignment algorithm [48].
Quantitative real-time RT-PCR
Total RNA was extracted from three biological replicates of
each cell line by using Trizol reagent (Invitrogen), and cDNA
was synthesized with Superscript II (Invitrogen) in accordance
with the manufacturer's instructions. Real-time primers were
designed with Primerquest Software [49]. Reactions in
Figure 1
Experimental design and chromosomal mapping of variably methylated targets Experimental design and chromosomal mapping of variably methylated targets. (a) Experimental design of methylation analysis with Affymetrix human 
promoter 1.0R microarray. In this adaptor-mediated, PCR-based approach to probe the microarrays, (i) DNA was digested with MseI, purified and 
then (ii) adaptors were ligated before (iii) a second digestion was performed with the methylation-sensitive HhaI enzyme. (iv) Samples were then 
PCR amplified and (v) these PCR products were fragmented, labeled, and hybridized to the Affymetrix Human Promoter 1.0R GeneChips. Open cir-
cles, unmethylated cytosines; filled circles, methylated cytosines. (b) The chromosomal location of variably methylated promoter array gene targets in 
the MDA-MB-468GFP-LN cells relative to the parental cell line are shown as red blocks and represent significant (P < 0.05) targets identified in at 
least two of three replicates.Available online http://breast-cancer-research.com/content/10/4/R62
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triplicate for each biological replicate used 1 × Brilliant SYBR
Green QPCR Master mix (Stratagene; VWR, Mississauga,
ON, Canada), 150 nM forward and reverse primers, 200 μM
dNTPs and cDNA derived from 100 ng of RNA. For each
gene, standard curves were generated by using cDNA derived
from 100, 33.3, 11.1, 3.7 or 1.2 ng of total RNA. For each bio-
logical replicate, relative amounts of each gene were deter-
mined by comparison with the standard curve. The 'unknown'
samples were then normalized to glyceraldehyde-3-phosphate
dehydrogenase, and the expression levels in the control
468GFP cells were normalized to 1 so that results could be
presented as a percentage of fold change, relative to the
control.
Ingenuity Pathways Analysis
Gene networks and canonical pathways representing key
genes were identified using the curated Ingenuity Pathways
Analysis (IPA) database [50]. The data set containing gene
identifiers and corresponding fold changes was uploaded into
the web-delivered application and each gene identifier was
mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base (IPKB). The functional analysis
identified the biological functions and/or diseases that were
most significant to the data sets. Fisher's exact test was per-
formed to calculate a P value determining the probability that
each biological function and/or disease assigned to the data
set was due to chance alone. The data set was mined for sig-
nificant pathways with the IPA library of canonical pathways,
using either (1) a ratio of the number of genes from the data
set that mapped to the pathway divided by the total number of
genes that mapped to the canonical pathway or (2) a Fisher's
exact test to calculate a P value determining the probability
that the association between the genes in the data set and the
canonical pathway was explained by chance alone. In addition,
networks were generated by using IPA as graphical represen-
tations of the molecular relationships between genes and
gene products. The intensity of genes (node) colour in the net-
works indicates the degree of hypermethylation (blue) or
hypomethylation (yellow). Nodes are displayed using various
shapes that represent the functional class of gene products.
Results
Variably methylated regions are spread across the 
genomes of 468GFP and 468LN cells
We undertook high-resolution DNA methylation profiling with
the Affymetrix human promoter microarray platform to identify
metastasis-related methylation differences between the
468GFP and 468LN cell lines. This single-chip technology is
composed of more than 4.6 million 25-base-pair probes tiled
across 10 to 12.5-kilobase regions and includes the transcrip-
tion start sites of more than 25,500 gene promoter
sequences. DNAs from the cell lines were used in an adaptor-
mediated, PCR-based approach to probe triplicate microar-
rays. In the 468LN cells, relative to the 468GFP cells, we iden-
tified 2,209 unique hypermethylated and 1,235 unique
hypomethylated regions in at least two of three replicates (P <
0.05; Figure 1b). These regions were spread across the
genome, and clustering of the methylation changes could be
identified across specific chromosome arms. For example,
enriched regions of hypermethylation events were identified
on chromosomes 6p, 7p, 11p/q, 18p and 19p/q, and similar
hypomethylated regions also could be identified (1p, 3q, 7q
and 20q). These regions were not uniform, however, because
there was evidence of interspersed hypermethylation and
hypomethylation events across many of the chromosomes.
The Affymetrix promoter microarrays provide a robust platform
that can identify gene-specific and regional differences in DNA
methylation patterns in this breast cancer metastasis model.
We found a high degree of reproducibility across the replicate
microarrays, with individual tracings virtually overlapping at the
chromosome level (Figure 2). Furthermore, interfacing the
Partek analysis software with the Blat tool of the UCSC
genome browser showed that signal reproducibility within
individual promoter regions was uniform down to the level of
individual probe tiles within these promoter sequences (data
not shown).
Ingenuity Pathways Analysis of differentially methylated 
gene targets
Annotated gene lists were created of the 2,209 significantly
hypermethylated (P < 0.05; Table 1) and 1,235 hypomethyl-
ated (P < 0.05; Table 2) gene targets identified in the 468LN
cells. Although no functional relationships were immediately
evident in these lists, the clustering of hypermethylation events
at 7p11.1 and our own karyotyping of these cell lines [51] sug-
gest that gene dosage events involving 7p coincide with gene-
specific hypermethylation events in this particular region. This
may specifically involve chromosomal deletions or duplications
that lead to differences in copy number between the two cell
lines. We used IPA to investigate the biological relevance of
the observed genome-wide methylation changes by categoriz-
ing our data set into biological functions and/or diseases (Fig-
ure 3a). We determined that promoter hypermethylation was
more common than hypomethylation at the genes identified in
each of these top eight functional categories. These broad cat-
egories each involved between 226 and 375 genes having
roles in cell signalling, cellular movement, cancer and other
functional categories. We also searched the gene lists to iden-
tify significant canonical pathways from the IPA library (Figure
3b). The top five pathways involve signaling pathways in which
approximately 30% of the genes display methylation changes.
For example, the ERK/MAPK signaling pathway consists of
193 genes, of which 15 were hypomethylated and 37 were
hypermethylated. The complete list of all the variably methyl-
ated genes identified in these top five pathways is presented
in Table 3. Network analysis was also performed to provide a
graphical representation of the biological relationships
between genes and gene products. The top four networks
related to the EGFR, TGFβ 1, TNF and MYC genes, with eachBreast Cancer Research    Vol 10 No 4    Rodenhiser et al.
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Figure 2
Mapping of genomic DNA methylation changes Mapping of genomic DNA methylation changes. Epigenetic 'heat' maps were generated of variably methylated targets located on each chromosome 
(chrn). Genes identified above the center lines are hypermethylated in the MDA-MB-468GFP-LN cells relative to the MDA-MB-468GFP cells; those 
below the center line are hypomethylated. The overlapping traces represent the individual replicates from each microarray.Available online http://breast-cancer-research.com/content/10/4/R62
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network involving approximately 35 hypermethylation and
hypomethylation events (Figure 4).
DNA methylation changes in genes involved in 
epithelial–mesenchymal transition
To complement these database-generated functional analy-
ses, we investigated the involvement of EMT in our breast can-
cer metastasis model on the basis of our previous
observations of distinct morphological differences between
these cell lines that showed a shift from an epithelial to a more
mesenchymal phenotype [39]. We generated an IPA network
that addressed the biological relationships between genes/
gene products implicated in EMT [40] and we overlaid our
methylation data set onto this network (Figure 5). These genes
include commonly used molecular markers of EMT showing
both increased and decreased levels of expression that phe-
notypically increase the capacity for migration, invasion and/or
the resistance to apoptosis [40]. Using the statistical parame-
ters described in the Materials and methods section to detect
significant changes in methylation status, we undertook
sodium bisulfite analysis (Figure 6a) for several genes in this
network.
We tested for and identified changes in methylation status at
several gene loci, including CDH1, CST6, EGFR and the tran-
scriptional regulators SNAI2 and ZEB2. The EGFR locus was
intriguing for several reasons, because we had initially visual-
ized a reproducibly significant hypermethylation 'spike' at the
7p11.2 region, which contains the EGFR gene (Figure 2) as
well as several other nearby gene targets on the list of hyper-
methylated gene targets. Sodium bisulfite analysis using prim-
ers specific to the EGFR promoter region (Figure 6a)
confirmed the presence of significant levels of DNA methyla-
tion within the EGFR promoter in 468LN cells (47% methyl-
ated), in contrast with the 468GFP cells (1% methylated). Two
other genes (CDH1 and CST6) displayed significant altera-
tions in CpG methylation in the 468LN cells (up to 80% CpG
methylation), in contrast with 1 to 12% in the 468GFP cells,
confirming the promoter microarray in silico analyses. In con-
trast, ZEB2 was markedly hypomethylated in the 468LN cells,
in contrast with the 468GFP cells (1% versus 68% methyla-
tion), whereas SNAI2 showed only moderate overall DNA
methylation differences (65% versus 61%) between the cell
lines. However, these particular bisulfite profiles suggest that
two separate SNAI2 allelic methylation patterns (namely
Table 1
Top 20 putative hypermethylated gene targets detected by promoter analyses of 468GFP and 468LN cells
Gene name Common name Chromosome Fold change
FK506 binding protein 9, 63 kDa FKBP9 7p11.1 6.02
EGFR-coamplified and overexpressed protein ECOP 7p11.2 5.89
Hypothetical protein MGC33530 MGC33530 7p11.2 5.07
LanC lantibiotic synthetase component C-like 2 LANCL2 7p11.2 4.72
Coiled-coil-helix–coiled-coil–helix domain containing 2 CHCHD2 7p11.2 4.55
Epidermal growth factor receptor EGFR 7p11.2 4.54
FK506 binding protein 9, 63 kDa FKBP9 7p11.2 3.99
Immunoglobulin heavy locus IGH@ 14q32.33 3.89
ATPase, H+, lysosomal 42 kDa, V1 subunit C1 ATP6V1C1 8q22.3 3.86
Beta 1,3-galactosaminyltransferase, polypeptide 1 B3GALNT1 3q25 3.45
Sec61 gamma subunit SEC61G 7p11.2 3.45
Kelch-like 26 (Drosophila) KLHL26 19p13.11 3.44
phospholipase C, gamma 2 PLCG2 16q24.1 3.41
Ubiquitin specific peptidase 49 USP49 6p21 3.20
Solute carrier family 22, member 6 SLC22A6 11q13.1 3.07
Similar to metallo-beta-lactamase superfamily protein LOC153364 5q14.3 3.05
Src homology 2 domain containing adaptor protein B SHB 9p12 3.05
Cholinergic receptor, nicotinic, delta CHRND 2q33 2.92
Down syndrome critical region gene 9 DSCR9 21q21.13 2.83
Membrane associated ring protein 8 C3HC4 10q11.21 2.75
The names and descriptions of the genes are given, as well as the fold change in hypermethylation in MDA-MB-468GFP-LN (468LN) cells relative 
to MDA-MB-468GFP (468GFP) cells.Breast Cancer Research    Vol 10 No 4    Rodenhiser et al.
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hypermethylated and hypomethylated) are present in the
468LN cell line. A similar methylation pattern also seems to be
present in the CDH1 clones, which may explain the non-iden-
tification of CDH1 by the initial microarray analyses as a signif-
icantly hypermethylated target in the 468LN cells.
Quantitative real-time RT-PCR (Figure 6b) showed that
expression of the hypermethylated CDH1, CST6 and EGFR
genes was decreased in 468LN cells, whereas the hypometh-
ylated ZEB2 gene was significantly increased relative to the
468GFP cells. SNAI2 expression was also significantly
expressed in 468LN cells, perhaps reflecting a subpopulation
of 468LN cells possessing a hypomethylated SNAI2 allele.
Our data suggest that epigenetic mechanisms contribute to
the gene expression changes observed with these two cell
lines in this breast cancer metastasis model and that these are
complex relationships that need to be validated on a gene-by-
gene basis.
Discussion
Previous studies addressing epigenetic contributions to
metastasis have primarily focused on mapping increased DNA
methylation levels within the promoter regions of individual
candidate genes [16,20,21]. These studies have therefore
provided only a limited understanding of the functional mech-
anisms related to metastasis that may be modulated epigenet-
ically, because in most cases only individual candidate genes
rather than pathways and/or gene networks have been impli-
cated. Here we have used promoter tiling microarrays and a
unique breast cancer metastasis model to provide a whole-
genome map of epigenetic changes related to cancer metas-
tasis. The Affymetrix promoter microarray platform provided
near-total coverage of CpG-rich regulatory regions in the
human genome, with the inclusion of more than 25,000 human
promoter regions, including 1,300 cancer-related genes. Our
cell-line model system consisted of a poorly metastatic MDA-
MB-468GFP human breast adenocarcinoma cell line and a
highly metastatic variant (468LN) that exhibits profound mor-
phological changes and an increased growth rate and pro-
duces extensive spontaneous lymph node metastases [39].
We directly mapped significant regions of variable DNA meth-
ylation to specific CpG islands by interfacing the imported
microarray data analyzed by the Partek Genomics Suite soft-
Table 2
Top 20 putative hypomethylated gene targets detected by promoter analyses of 468GFP and 468LN cells
Description Gene symbol Chromosome Fold change
Chromogranin A (parathyroid secretory protein 1) CHGA 14q32 6.44
DKFZP434B0335 protein DKFZP434B0335 7q21.3 3.73
Zinc finger, C3HC-type containing 1 ZC3HC1 7q32.2 3.41
Centrosomal protein 57 kDa CEP57 11q21 3.22
Stromal antigen 1 STAG1 3q22.3 3.12
Vesicle-associated membrane protein 3 (cellubrevin) VAMP3 1q36.23 3.07
Ectonucleoside triphosphate diphosphohydrolase 7 ENTPD7 10q24.2 2.98
Transmembrane emp24 domain trafficking protein 2 TMED2 12q24.31 2.97
Glycoprotein V (platelet) GP5 3q29 2.96
CATR tumorigenicity conversion 1 CATR1 7q32 2.87
Nuclear receptor subfamily 2, group C, member 2 NR2C2 3p25 2.83
Small EDRK-rich factor 1A (telomeric) SERF1A 5q12.2-q13.3 2.83
Transcription factor 12 TCF12 15q21 2.82
Zinc finger and BTB domain containing 20 ZBTB20 3q13.2 2.82
Aurora kinase A interacting protein 1 AURKAIP1 1p36.33 2.82
Sorting nexin 1 SNX1 15q22.31 2.82
LOC136263 LOC136263 7q32.2 2.81
NEDD8 ultimate buster-1 NYREN18 7q36 2.77
Testis specific, 13 TSGA13 7q32 2.76
Solute carrier family 3A, member 2 SLC3A2 11q13 2.75
The names and descriptions of the genes are given, as well as the fold change in hypomethylation in MDA-MB-468GFP-LN (468LN) cells relative 
to MDA-MB-468GFP (468GFP) cells.Available online http://breast-cancer-research.com/content/10/4/R62
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ware [42] with the UCSC genome browser. We used IPA to
mine the large data sets that were generated with Affymetrix
promoter microarray platforms and to identify genes belonging
to functional categories (Figure 3a) and specific canonical
pathways (Figure 3b and Table 3). Functional pathway analy-
sis revealed that multiple epigenetic changes were identified
within several broad, all-encompassing biological pathways.
Similarly, canonical pathway analysis revealed the involvement
of epigenetic targets in signalling pathways linked to metasta-
sis [10,52]. Interestingly, it seems that epigenetic events con-
sistently involve 25 to 30% of the genes in each of these
signalling pathways (Figure 3b), suggesting that these epige-
netic changes represent a common yet poorly studied mecha-
nism contributing to the metastatic process. In addition, these
epigenetically sensitive pathways may represent common
therapeutic targets for epigenetic-based chemotherapies that
can restore the normal epigenetic and expression patterns of
genes [53].
We also identified gene networks displaying epigenetic
changes in our breast cancer metastasis model system that
may correlate with specific epigenetic/gene-expression
changes in the context of lymphatic metastasis. First, we used
the curated Ingenuity literature database to identify networks
of genes having known biological relationships to each other.
As shown in Figures 4 and 5, the top significant networks
include both hypermethylated and hypomethylated genes.
One network focused on the EGFR gene (Figure 4) and
involved 14 hypomethylated and 20 hypermethylated genes,
including members of the KCNA family of potassium voltage-
gated channel genes and the receptor tyrosine kinase ERBB3.
The absence of EGFR methylation in the 468GFP cells
confirmed a previous report [54] showing that several breast
cancer cell lines, including the parental MDA-MB 468 cells,
lack DNA methylation at the EGFR promoter. The hypermeth-
ylated status of EGFR in the 468LN cells predicted by the
microarray and Ingenuity analysis was verified by sodium
bisulfite analysis and furthermore was associated with
decreased expression of this gene in comparison with the
parental 468GFP cell line (Figure 6). This hypermethylation,
along with the repressed EGFR expression that we observe in
the 468LN cells, is somewhat paradoxical in that EGFR
expression (a known oncogenic characteristic of cancer cells)
has apparently been selected against in the more metastatic
468LN cell line.
The three other most significant networks we identified were
focused on the TNF, TGFβ 1 and MYC genes. Each of these
networks possessed about 36 genes having altered DNA
methylation profiles (Figure 4). Our data support previous
reports that have also suggested the involvement of epige-
netic regulation and/or roles in chromatin remodelling for
Table 3
Gene lists identified from the canonical pathway analyses shown in Figure 3b
Canonical pathway Hypermethylated Hypomethylated
ERK/MAPK signaling ARAF, CREB3, CREB5, DUSP4, EGFR, ELF3, FGFR3, 
FGFR4, FYN, HSPB2, LTK, MERTK, MKNK1, MYCN, 
PIK3R2, PIK3R3, PIK3R5, PLCG2, PPM1J, PPP1CB, 
PPP1R10, PPP1R11, PPP1R14A, PPP2R1B, PRKACG, 
PRKAG2, PRKAR1A, PRKCG, RAC1, RAC2, RAPGEF1, 
RAPGEF4, ROR2, RPS6KA5, SHC1
ATF4, ELK1, ESR1, FOS, MAPKAPK5, MRAS, MYC, 




ADAM2, ADAM30, ARHGEF12, BAIAP2, BDNF, BMP6, 
BMP8A, BMP8B, CFL2, DPYSL5, EFNB3, EGFR, EPHA10, 
EPHA8, EPHB1, FGFR3, FGFR4, FYN, GLI1, GLI2, GNAL, 
GNAO1, GNAT2, GNG3, L1CAM, LTK, MAG, MERTK, 
MICAL1, MKNK1, MYL5, MYL7, NFATC1, NFATC4, NGFB, 
NTF5, PIK3R2, PIK
ABLIM1, ADAM9, BMP15, CDC42, EPHA3, EPHB4, 
GNAS, KALRN, MRAS, MYL3, NFATC2, NTF3, 
NTN2L, PIK3CA, PRKACA, PRKCD, ROBO1, SMO, 
SRGAP3, WASL, WNT16, WNT2
B-cell receptor 
signaling
BCL10, BCL2A1, BCL3, CALM3, CAMK2B, CARD10, 
CREB3, CREB5, GSK3A, INPP5D, LYN, MAP2K4, 
MAP3K11, MAPK13, NFATC1, NFATC4, NFKBIE, PIK3R2, 
PIK3R3, PIK3R5, PLCG2, POU2F2, PRKCQ, PTEN, RAC1, 
RAC2, RELA, SHC1
ATF4, BCL6, CDC42, CHUK, ELK1, FCGR2A, 
FCGR2B, FCGR2C, MAP2K7, MRAS, NFATC2, 
PIK3CA
Integrin signaling ACTA1, ACTB, ACTG2, ACTN3, ACTN4, BCAR3, CAPN5, 
CAPN9, CAPNS1, EGFR, FGFR3, FGFR4, FYN, ITGAX, 
LTK, MAP2K4, MAP3K11, MERTK, MRCL3, MRLC2, MYL5, 
MYL7, PIK3R2, PIK3R3, PIK3R5, PLCG2, PPP1CB, PTEN, 
RAC1, RAC2, RALA, RAPGEF1, RHOC, RHOT2, ROR2, 
SHC1, TLN1, TN
ARF5, CAV1, CDC42, DDEF1, ITGA10, ITGB2, 
MRAS, MYLK, PIK3CA, TSPAN3, WASL
Huntington's disease 
signaling
BDNF, BET1L, CACNA1B, CAPN5, CAPN9, CAPNS1, 
CREB3, CREB5, DNM3, EGFR, GNG3, HAP1, HSPA1A, 
HSPA1B, HSPA2, HSPA8, IGF1R, MAP2K4, MAPK13, 
NAPA, NAPG, NCOR2, NGFB, PACSIN1, PIK3R2, PIK3R3, 
PIK3R5, POLR2C, POLR2D, POLR2H, POLR2J, PRKCG, 
PRKCH, PRKCQ, SHC1, SNA
ATF4, CASP2, CASP4, DLG4, DNAJC5, EP300, 
HDAC7A, MAP2K7, MAPK6, PIK3CA, PRKCD, 
SDHA, SDHB, STX16, VAMP3, YKT6Breast Cancer Research    Vol 10 No 4    Rodenhiser et al.
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these genes. For example, the TNF network includes the activ-
ity-dependent neuropeptide protein (ADNP), a novel element
of SWI/SNF chromatin remodelling complexes that downreg-
ulates TNF and may be important in immune surveillance and
cancer [55,56]. In addition, concordant epigenetic silencing of
TGFβ signaling pathway genes has been widely reported in
breast carcinogenesis [57]. MYC overexpression is commonly
implicated in breast cancer and metastasis [58], and certain T-
cell lymphomas overexpressing MYC possess specific hyper-
methylation signatures [59].
We also directly addressed molecular mechanisms responsi-
ble for the phenotypic characteristics observed in our meta-
static breast cancer model. Given the marked morphological
differences in vitro between these cell lines [39], we mapped
the biological association of 35 focus genes reported to be
associated with EMT [40]. The resultant network (Figure 5)
showed that epigenetic changes could be identified at several
of these gene loci, including EGFR, the lysosomal cysteine
protease inhibitor cystatin M (CST6) [60] and the transcrip-
tional repressors ZEB2 and SNAI2. SNAI2, Zeb2 and other
family members have multiple gene targets and can recruit
specific chromatin-remodelling complexes that repress E-cad-
herin (CDH1), which is frequently downregulated in tumor pro-
gression and EMT [61] and implicated in lymph node
metastasis [23]. CDH1 did not exceed the initial significance
levels set to triage differentially methylated candidate genes,
but this gene was nevertheless chosen for analysis given its
role as a common target for epigenetic inactivation in metasta-
sis [21] and its functional relationship to other genes in the
EMT network. Sodium bisulfite analysis confirmed the methyl-
ation status of each of these genes (Figure 6) and we identi-
fied high levels of methylation in the CpG-rich promoter
regions of CDH1, EGFR and CST6, as well as hypomethyla-
tion at the Zeb2 regulatory region, in the 468LN cells. While
the promoter microarrays identified significant hypomethyla-
tion in the SNAI2 promoter in 468LN cells, bisulfite analysis
suggested only modest changes in methylation levels at this
gene locus. Interestingly, sodium bisulfite profiles revealed the
existence of two populations of SNAI2 clones, one of which
was completely demethylated. This suggests that the 468LN
cells may include a population of cells in which this gene is
Figure 3
Top functional categories and canonical pathways identified by IPA Top functional categories and canonical pathways identified by IPA. (a) Top eight functional categories from our data set based on significance. The 
red line (T) indicates the threshold of – logP greater than 2.0. The total numbers of genes (for example 375) and the relative numbers of significant 
hypomethylated and hypermethylated genes are shown for each category. (b) Top five pathways from the Ingenuity Pathways Analysis library of 
canonical pathways that were most significant to our data set. For each canonical pathway, hypomethylated (yellow) and hypermethylated (blue) 
genes are shown (for example 15 and 37), as is the total number of genes in that pathway (for example 193). The top axis represents the percentage 
of genes per pathway, and the bottom axis the significance (red data points).Available online http://breast-cancer-research.com/content/10/4/R62
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Figure 4
Network diagrams generated as a graphical representation of the molecular relationships between genes and gene products Network diagrams generated as a graphical representation of the molecular relationships between genes and gene products. The gene products are 
represented as nodes (shapes) and the biological relationship between two nodes is represented as an edge (line). All edges are supported by at 
least one reference stored in the Ingenuity Pathways Knowledge Base. The intensity of the node color indicates the degree of hypermethylation 
(blue) or hypomethylation (yellow) and the nodes are displayed using various shapes that represent the functional class of the gene product (the key 
is given in Figure 5).Breast Cancer Research    Vol 10 No 4    Rodenhiser et al.
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hypomethylated and overexpressed. We also determined the
functional significance of epigenetic changes observed at
these loci by performing qRT-PCR (Figure 6b). The hyper-
methylated status of CDH1, EGFR and CST6 was associated
with significant repression of these genes in the 468LN cells,
whereas hypomethylation of Zeb2 was consistent with its
upregulation in these cells. We also observed marked upreg-
ulation of the other transcriptional repressor SNAI2, despite
only limited or modest changes in DNA methylation observed
by bisulfite analysis.
Overall, we showed that over 3,400 genes exhibit altered
methylation patterns between these two cell lines, with most
of the methylation changes observed in the 468LN cells being
hypermethylation events (64%). This relatively high frequency
of hypermethylation is probably related to technical character-
istics of the Affymetrix platform, which used sequences
selected from the National Center for Biotechnology Informa-
tion human genome assembly (Build 34) with repetitive ele-
ments removed by Repeatmaster. We also observed that a
proportion of these methylation changes seemed to be clus-
tered within particular genomic regions (Figure 1b and Table
1). This suggested to us that either certain chromosomal sub-
regions are hypermethylated (or hypomethylated) in a coordi-
nated manner, or regional gene-dosage events are masking or
biasing some epigenetic events at certain loci. Support for this
latter possibility comes from G-banding, spectral karyotyping
and fluorescence in situ hybridization of both cell lines by our
group, which has revealed multiple different chromosome
aberrations [51]. In particular, our karyotyping analysis
showed differences in the modal chromosome number
between the cell lines (60 for 468GFP, and 55 for 468LN), as
well as the presence of chromosome alterations that are
unique to each of the cell lines. For example, the 468GFP cells
possessed an isochromosome [i(7)(p10)], whereas this deriv-
ative chromosome was absent in the 468LN cell line. In con-
trast, the 468LN cells possessed a derivative chromosome 8
[der(8);t(8;15)(q22;q24)] that is absent in the parental cell
line. Our subsequent methylation analysis in the context of
these complex karyotypic differences suggests that at certain
loci, methylation detection may be dependent on gene dosage
within these specific chromosome regions. For example, our
microarray analyses of EMT-related genes identified EGFR
and TWIST1 (on the duplicated 7p) as hypermethylated,
whereas bisulfite sequencing confirmed the hypermethylated
status of only EGFR in the 468LN cells (Figure 6a). In addition,
Figure 5
IPA network of genes associated with epithelial–mesenchymal transition IPA network of genes associated with epithelial–mesenchymal transition. This network diagram shows the biological associations of 35 focus genes 
associated with epithelial–mesenchymal transition [40] as a graphical representation of the molecular relationships between genes/gene products. 
The intensity of the node color indicates the degree of hypermethylation (blue) or hypomethylation (yellow) above the significance cutoff and the 
nodes are displayed using various shapes that represent the functional classes of the gene products as shown in the key.Available online http://breast-cancer-research.com/content/10/4/R62
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these microarrays predicted SNAI2 and HEY1 (on chromo-
some 8q11-21) as hypomethylated, with bisulfite sequencing
confirming that only SNAI2 was hypomethylated in the 468LN
cells.
Our data suggest that the complex genomic reorganization
present in cancer cells (for example unbalanced translocations
and deletions) may be superimposed over promoter-specific
methylation events that may subsequently be responsible for
gene-specific expression changes. We believe that it is there-
fore of critical importance, in such whole-genome epigenetic
profiling experiments, to validate promoter methylation status
at specific loci by bisulfite sequencing or similar methods. In
addition, given the complex relationship between both genetic
and epigenetic mechanisms in initiating and maintaining the
steps involved in metastasis [11,23], such experiments to
validate methylation profiles should be performed concurrently
with gene expression studies, to rule out the presence of false
positives (or negatives) and to ensure that methylation effects
directly repress gene promoter/enhancer regions. Finally, we
propose that the concurrent use of either comparative
genomic hybridization or single nucleotide polymorphism/
copy-number variation microarrays may be warranted to corre-
late epigenetic and gene expression patterns with differences
in gene copy number between cancer cell lines. Such an
approach would permit multi-platform analyses that link
together genetic, epigenetic and genomic contributions to
cancer progression.
Conclusion
Our use of promoter microarray technology provides a power-
ful whole-genome approach with which to identify specific epi-
genetic events that may correlate with particular steps in
metastatic progression, such as EMT. This approach will also
allow the development of epigenetic signatures of metastasis
to be used concurrently with genomic signatures to enable
better mapping of the evolving molecular landscape on which
metastasis occurs. As a result, diagnostic, prognostic and
therapeutic markers that correlate epigenetic and genetic
changes can be identified. One important caveat relates to the
importance of validating specific epigenetic changes by using
alternative methods of methylation analysis as well as the
necessity to link specific epigenetic changes functionally with
gene expression. In this manner, specific changes in gene
expression such as those that we identify as being associated
with EMT will permit translational approaches to target altered
molecular pathways related to metastatic progression in these
cells.
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